Abcam purchases assets from Applied StemCell

Abcam Australia Pty Ltd

Monday, 10 February, 2020


Abcam, a global innovator in life science reagents and tools, has announced the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell (ASC) for life science research and diagnostic markets.

ASC is a leader in the edited cell lines market, focused on developing genome editing technologies into novel therapeutics to advance drug discovery. Over the last 11 years the company has established a reputation for solving the most difficult knock-out and knock-in cell line development challenges, having successfully deployed its proprietary cell editing platform to create cell lines for a broad range of diseases to support the life science and diagnostics industries as well as to advance therapeutic drug discovery.

The Abcam transaction includes a portfolio of cell lines and the AccuRef reference materials product line. The AccuRef line uses ASC gene-edited cell lines to mimic cancer mutations and create biologically relevant quality control and reference standards that span over 40 cancer genes. These materials are used by laboratories and kit providers for next-generation sequencing, sanger sequencing, PCR and FISH/CISH testing.

Abcam will expand the ASC platform to become its discovery engine for developing novel edited cell lines, building on the extensive range of knock-out cell lines acquired through its Edigene transaction in 2019. Ready-made KO cell lines play a significant role in the study and understanding of biological pathways and disease models.

Cheri Walker, SVP of Corporate Development at Abcam, said, “We are excited to expand and cement Abcam’s position in the edited cell line market, bringing one of the most widely deployed and technically successful cell engineering platforms into the Abcam family. The cell line market is in the early stages of development as a research tool, where the ready provision of more choice, with the right gene targets in the right cell lines, will allow the market to rapidly expand.“

Ruby Tsai, co-founder and CSO of Applied StemCell, added, “Following our strategic decision to focus on stem cell and derivative service and products for both research and therapeutic applications, we are pleased to be transitioning our oncology-focused services and products to the global team at Abcam. As recognised industry leaders in the provision of biologic reagents and tools, Abcam is ideally placed to provide expert support to our global user base.”

With the transaction having closed on 28 January, both parties will now work together over a transition period to ensure continuity of service and project delivery. In addition, ASC’s portfolio and cell engineering capability will be deployed to further support Abcam’s knock-out validation initiative — an integral part of the organisation’s ongoing antibody quality initiative.

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Updated standard to reduce errors in medical laboratories

ISO 22367 specifies a process for a medical laboratory to identify and manage the risk to...

NHMRC presents 2019 Research Excellence Awards

Research Excellence Awards are awarded each year to top-ranked researchers and teams following...

Thermo Fisher announces new appointment, QIAGEN acquisition

Thermo Fisher Scientific has proposed to acquire QIAGEN and appointed Paul G Parker as Senior...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd